Lipigon Pharmaceuticals AB (LPGO) — Capital Reinvestment Ratio

Latest as of March 2020: 0.39x

Lipigon Pharmaceuticals AB (LPGO) has a Capital Reinvestment Ratio of 0.39x as of March 2020, meaning it reinvests 0% of its operating cash flow (Skr309.00K) in capital expenditures (Skr119.00K). See LPGO equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.39x
Capex / Operating Cash Flow

Operating Cash Flow

Skr309.00K
SEK

Capital Expenditures

Skr119.00K
SEK

Data as of

Mar 2020
Most recent filing

Annual Capital Reinvestment Ratio for Lipigon Pharmaceuticals AB (None–None)

Year-by-year Capital Reinvestment Ratio for Lipigon Pharmaceuticals AB from None to None. For live market cap and broader valuation context, see market cap of Lipigon Pharmaceuticals AB.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow